Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The retinoblastoma (Rb) and p53 tumor suppressor pathways are frequently corrupted in human cancers, leading to uncontrolled cell proliferation.
• This corruption provides oncogene-bearing cancer cells with excessive Cyclin-Dependent Kinase (Cdk) activity, promoting evasion of tumor suppression.
• Targeting both Cdk activity and the Phosphatidylinositol 3-Kinase (PI3K) pathway presents a potential universal strategy for cancer therapy.

Purpose of the Study:

• To investigate the efficacy of purine-based Cdk inhibitors, such as roscovitine, in combination with a PI3K inhibitor (LY294002) across various cancer cell types.
• To determine how the integrity of the Rb and p53 pathways influences the cytotoxicity of these targeted agents.
• To explore the impact of cell culture conditions, specifically serum concentration, on the differential cytotoxicity of closely related purine compounds.

Main Methods:

• Assessed the killing efficacy of roscovitine and 16 other purine analogs on cancer cells with varying Rb and p53 pathway status.
• Evaluated the potentiation of roscovitine-induced apoptosis by the PI3K inhibitor LY294002.
• Compared the cytotoxicity profiles of purine compounds in rich versus poor medium conditions to identify off-target effects.

Main Results:

• The cytotoxic efficacy of roscovitine and other purines, as well as the potentiation by LY294002, decreased with increasing corruption of the Rb and p53 pathways.
• Closely related purine compounds exhibited distinct cytotoxicity profiles depending on the cell type and medium conditions (rich vs. poor serum).
• These findings suggest that compounds targeting similar Cdks may interact with different off-targets, influencing therapeutic outcomes.

Conclusions:

• The effectiveness of Cdk inhibitors, particularly in combination with PI3K inhibitors, is significantly influenced by the Rb and p53 pathway status of cancer cells.
• Cell culture conditions, especially serum concentration, are critical for revealing differential target engagement and potential off-target interactions of Cdk inhibitors.
• Clinical development of Cdk inhibitors should involve careful selection of tumor cell type-specific agents based on toxicity assays performed under low-serum conditions to minimize off-target effects.